<DOC>
	<DOCNO>NCT00602784</DOCNO>
	<brief_summary>The objective 1. determine immunological profile ( CD4+ , CD8+ cell , DTH ) induce immunization HCV antigen peptide vaccine polyarginine . 2. document virological ( HCV-RNA ) biochemical ( ALT ) responses follow immunization HCV antigen peptide vaccine polyarginine . 3. assess safety immunization HCV antigen peptide vaccine polyarginine .</brief_summary>
	<brief_title>Phase II Study Immunization With Hepatitis C Virus ( HCV ) Antigen Peptide Vaccine</brief_title>
	<detailed_description>This double blind , randomize , parallel group , control , multicenter phase II study . 60 patient enrol assign one 5 dose control group . Each study group include 8 patient . Each patient receive total 6 injection accord dose assign study group . The injection administer subcutaneously upper arm every four week 5 month , i.e . day 1 , 29 , 57 , 85 , 113 141 . The volume injection 0.5 ml group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis chronic hepatitis C Nonresponse relapse primary standard HCV therapy HLA A2 positive HCVRNA positive HCV antibody positive Liver biopsy within 30 month prior inclusion Hematology biochemistry laboratory result within limit normally expect patient population ( liver value maximal 5 time upper limit normal ) Male female From 18 65 year Written inform consent obtain prior study entry Any degree liver cirrhosis fibrosis Ishak score â‰¥ 4 ( grade table , see APPENDIX 2 : The Ishak Modified Hepatic Activity Index ( HAI ) ) Any liver disease hepatitis C History autoimmune disease Immunodeficiency include postorgantransplantation HIV infection Immunosuppressive therapy Any acute infection within 4 week prior inclusion History severe hypersensitivity reaction , anaphylaxis atopy Diabetes mellitus , severe cardiopulmonary disorder , history malignancy past 5 year Active passive vaccination within 2 month prior enrolment , concomitant vaccination throughout study period Pregnancy lactation Unreliable contraception Alcohol consumption Drug abuse addiction within 12 month prior inclusion Participation methadone program Participation another study within 1 month prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>